Skip to main content
OpenTrials
Completed

NCT Number: NCT04725877

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo. These participants will be assessed for safety, reactogenicity, tolerability and immunogenicity. There is an optional long-term follow-up study that would lengthen study participation for up to 3 years post-first dose.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV I Infection

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Investigative Site, Miami, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males or healthy females of non-child-bearing potential between the ages of 18 to 50 at the time of screening
  • Positive CMV serostatus
  • Assessed by clinic staff as being low risk for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last protocol visit
  • Willing to use condoms during intercourse through Week 36 or the end of the study
  • Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
  • Willing to comply with the protocol requirements regarding donation of blood, sperm or other tissues
  • In the opinion of the Investigator, generally in good health as determined from medical history and no clinically significant findings from physical examinations, vital signs, and laboratory values

Exclusion criteria

  • Live in a home with children under the age of 6
  • Routine provision of child care to children under the age of 6
  • Have close contact with immunocompromised individuals
  • Have close contact with pregnant women or a partner planning to become pregnant during the course of the study
  • Health care provider who routinely comes into contact with immunosuppressed patients or pregnant women
  • Participant is immunocompromised
  • Participant has an autoimmune disorder
  • Positive HIV test at the time of study screening
  • Receipt of another investigational HIV or CMV vaccine candidate

Treatment and study plan

VIR-1111

Biological

VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.

Placebo

Drug

A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.

Primary outcomes

  1. Number of participants with any treatment-emergent adverse events (AEs)

    Time frame: Day 1 through 36 weeks

    A treatment-emergent AE is any AE with an onset date on or after the investigational product start date and no later than 36 weeks after permanent discontinuation of the investigational product.

  2. Number of participants with any serious AEs (SAEs)

    Time frame: Day 1 through 36 weeks

    An SAE is any life-threatening event or one that results in hospitalization, significant disability/incapacity, death or congenital anomaly/birth defect.

  3. Number of participants with any local site reactogenicity event after first dose

    Time frame: Day 1 through 14 days after first dose

    Signs and symptoms will be captured at the injection site (e.g., pain/tenderness, swelling, redness and induration) through self-assessment via participant diaries and in-person clinical assessments.

  4. Number of participants with any local site reactogenicity event after second dose

    Time frame: Day 1 through 14 days after second dose

    Signs and symptoms will be captured at the injection site (e.g., pain/tenderness, swelling, redness and induration) through self-assessment via participant diaries and in-person clinical assessments.

  5. Number of participants with any systemic reactogenicity event after first dose

    Time frame: Day 1 through 14 days after first dose

    Systemic signs and symptoms (fever, headache, fatigue, arthralgia, myalgia, malaise, nausea, vomiting or chills) through self-assessment via participant diaries and in-person clinical assessments.

  6. Number of participants with any systemic reactogenicity event after second dose

    Time frame: Day 1 through 14 days after second dose

    Systemic signs and symptoms (fever, headache, fatigue, arthralgia, myalgia, malaise, nausea, vomiting or chills) through self-assessment via participant diaries and in-person clinical assessments.

  7. Number of participants with any treatment-emergent clinical laboratory abnormalities (chemistry, hematology and liver function tests)

    Time frame: Day 1 through 36 weeks

    A treatment-emergent clinical laboratory abnormality is a clinical laboratory value that increases at least 1 toxicity grade from baseline at any postbaseline timepoint up to 30 days after permanent discontinuation of study drug. Clinical laboratory abnormalities are graded using DAIDS Table for Grading and Severity of Adult and Pediatric Events, Corrected Version 2.1, July 2017.

  8. Number of participants with CMV vector viremia (blood)

    Time frame: Day 1 through 36 weeks

    Quantitative polymerase chain reaction (qPCR) for CMV will be performed on participant blood samples collected throughout the study. Positive samples will undergo follow-up confirmatory PCR testing to differentiate wild-type CMV from CMV vaccine vector sequences.

  9. Number of participants with CMV vector shedding (urine and saliva)

    Time frame: Day 1 through 36 weeks

    Quantitative polymerase chain reaction (qPCR) for CMV will be performed on both saliva and urine samples collected from participants throughout the study to monitor for viral shedding. Positive samples will undergo follow-up confirmatory PCR testing to differentiate wild-type CMV from CMV vaccine vector sequences.

Secondary outcomes

  1. Frequency of CMV-specific CD8 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect IL-2 AND/OR IFNg AND/OR TNFa

    Time frame: 0-36 weeks

  2. Frequency of CMV-specific CD4 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect IL-2 AND/OR IFNg AND/OR CD154

    Time frame: 0-36 weeks

  3. Frequency of HIV-1 Clade A Gag-specific CD4 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect IL-2 AND/OR IFNg AND/OR TNFa AND/OR CD154

    Time frame: 0-36 weeks

  4. Frequency of HIV-1 Clade A Gag-specific CD8 T cells T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect IL-2 AND/OR IFNg AND/OR TNFa

    Time frame: 0-36 weeks

  5. Memory phenotype of CMV-specific CD4 T cells via flow cytometry analysis of CD45RA, CCR7, CD27, CD28 AND/OR CD95.

    Time frame: 0-36 weeks

  6. Memory phenotype of CMV-specific CD8 T cells via flow cytometry analysis of CD45RA, CCR7, CD27, CD28 AND/OR CD95

    Time frame: 0-36 weeks

  7. Memory phenotype of HIV-1 Clade A Gag-specific CD4 T cells via flow cytometry analysis of CD45RA, CCR7, CD27, CD28 AND/OR CD95

    Time frame: 0-36 weeks

  8. Memory phenotype of HIV-1 Clade A Gag-specific CD8 T cells via flow cytometry analysis of CD45RA, CCR7, CD27, CD28 AND/OR CD95

    Time frame: 0-36 weeks

  9. Binding titers of CMV-specific IgG antibodies

    Time frame: 0-36 weeks

  10. Binding titers of HIV Clade A Gag-specific IgG antibodies

    Time frame: 0-36 weeks

Sponsors and collaborators

Lead sponsor

Vir Biotechnology, Inc.

Industry

Collaborators

  • Bill and Melinda Gates Foundation

Registry information

Official study title

A Phase 1a, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Jan 27, 2021
Registry last updated
Feb 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.